Leukemia Treatment Breakthrough
Adding Rituxan to standard chemotherapy for chronic lymphocytic leukemia raises three-year survival to 65% and is now the gold standard therapy for most patients.
Click here to read the full story.
No profanity or inappropriate comments will be allowed.
Offensive posters will be blocked from future postings.
The content has been reported and it will be reviewed by a moderator.
